BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 14625887)

  • 21. The state of the prion.
    Weissmann C
    Nat Rev Microbiol; 2004 Nov; 2(11):861-71. PubMed ID: 15494743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distribution of the cellular prion protein (PrPC) in brains of livestock and domesticated species.
    Díaz-San Segundo F; Salguero FJ; de Avila A; Espinosa JC; Torres JM; Brun A
    Acta Neuropathol; 2006 Nov; 112(5):587-95. PubMed ID: 16957924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The neurochemical nature of PrP(c)-containing cells in the rat brain.
    Moleres FJ; Velayos JL
    Brain Res; 2007 Oct; 1174():143-51. PubMed ID: 17854776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prion proteins: physiological functions and role in neurological disorders.
    Hu W; Kieseier B; Frohman E; Eagar TN; Rosenberg RN; Hartung HP; Stüve O
    J Neurol Sci; 2008 Jan; 264(1-2):1-8. PubMed ID: 17707411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New insights into cellular prion protein (PrPc) functions: the "ying and yang" of a relevant protein.
    Nicolas O; Gavín R; del Río JA
    Brain Res Rev; 2009 Oct; 61(2):170-84. PubMed ID: 19523487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of oligomeric prion-protein aggregates in a mouse model of prion disease.
    Sasaki K; Minaki H; Iwaki T
    J Pathol; 2009 Sep; 219(1):123-30. PubMed ID: 19479969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Altered prion protein glycosylation in the aging mouse brain.
    Goh AX; Li C; Sy MS; Wong BS
    J Neurochem; 2007 Feb; 100(3):841-54. PubMed ID: 17144900
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PrP(Sc) of scrapie 263K propagates efficiently in spleen and muscle tissues with protein misfolding cyclic amplification.
    Shi S; Dong CF; Wang GR; Wang X; An R; Chen JM; Shan B; Zhang BY; Xu K; Shi Q; Tian C; Gao C; Han J; Dong XP
    Virus Res; 2009 Apr; 141(1):26-33. PubMed ID: 19162101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Octapeptide repeat region of prion protein (PrP) is required at an early stage for production of abnormal prion protein in PrP-deficient neuronal cell line.
    Sakudo A; Wu G; Onodera T; Ikuta K
    Biochem Biophys Res Commun; 2008 Jan; 365(1):164-9. PubMed ID: 17981146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Green tea extracts interfere with the stress-protective activity of PrP and the formation of PrP.
    Rambold AS; Miesbauer M; Olschewski D; Seidel R; Riemer C; Smale L; Brumm L; Levy M; Gazit E; Oesterhelt D; Baier M; Becker CF; Engelhard M; Winklhofer KF; Tatzelt J
    J Neurochem; 2008 Oct; 107(1):218-29. PubMed ID: 18691383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening a library of potential prion therapeutics against cellular prion proteins and insights into their mode of biological activities by surface plasmon resonance.
    Touil F; Pratt S; Mutter R; Chen B
    J Pharm Biomed Anal; 2006 Mar; 40(4):822-32. PubMed ID: 16242887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nucleic acid and prion protein interaction produces spherical amyloids which can function in vivo as coats of spongiform encephalopathy agent.
    Nandi PK; Nicole JC
    J Mol Biol; 2004 Nov; 344(3):827-37. PubMed ID: 15533448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Molecular bases of prion diseases].
    Rać M; Rać M
    Ann Acad Med Stetin; 2006; 52(3):5-13. PubMed ID: 17385343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tissue plasminogen activator in brain tissues infected with transmissible spongiform encephalopathies.
    Xanthopoulos K; Paspaltsis I; Apostolidou V; Petrakis S; Siao CJ; Kalpatsanidis A; Grigoriadis N; Tsaftaris A; Tsirka SE; Sklaviadis T
    Neurobiol Dis; 2005 Nov; 20(2):519-27. PubMed ID: 15922607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein.
    Wong C; Xiong LW; Horiuchi M; Raymond L; Wehrly K; Chesebro B; Caughey B
    EMBO J; 2001 Feb; 20(3):377-86. PubMed ID: 11157745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unraveling the details of prion (con)formation(s): recent advances by mass spectrometry.
    Principe S; Maras B; Schininà ME; Pocchiari M; Cardone F
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):697-707. PubMed ID: 18729021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prion diseases: from molecular biology to intervention strategies.
    Nunziante M; Gilch S; Schätzl HM
    Chembiochem; 2003 Dec; 4(12):1268-84. PubMed ID: 14661267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regional and phenotype heterogeneity of cellular prion proteins in the human brain.
    Kuczius T; Koch R; Keyvani K; Karch H; Grassi J; Groschup MH
    Eur J Neurosci; 2007 May; 25(9):2649-55. PubMed ID: 17466020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuroendocrine cultured cells counteract persistent prion infection by down-regulation of PrPc.
    Aguib Y; Gilch S; Krammer C; Ertmer A; Groschup MH; Schätzl HM
    Mol Cell Neurosci; 2008 May; 38(1):98-109. PubMed ID: 18387818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Semiautomated cell-free conversion of prion protein: applications for high-throughput screening of potential antiprion drugs.
    Breydo L; Bocharova OV; Baskakov IV
    Anal Biochem; 2005 Apr; 339(1):165-73. PubMed ID: 15766724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.